Portal Vein Thrombosis: A Detailed Review of Etiology, Diagnosis, and Treatment Volume 62- Issue 4

Ali Chand¹, Muhammad Ahmad Imran², Musa Khalil¹, Muhammad Hassan¹, Qurrat ul ain Iqbal³, PINKY BAI¹, Mudasir Rashid²*, Bisma Farooq³ and Angesom Kibreab⁴

• ¹Department of Medicine, Howard University Hospital, USA
• ²Cancer Center, Howard University Hospital, USA
• ³Department of Medicine, Shaikh Zayed Post Graduate Medical Complex, Pakistan
• ⁴Department of Gastroenterology, Howard University Hospital, USA

Received: June 22, 2025; Published: July 14, 2025

*Corresponding author: Mudasir Rashid, Cancer Center, Howard University Hospital, Washington, DC, USA

DOI: 10.26717/BJSTR.2025.62.009776

Abstract PDF

ABSTRACT

Portal vein thrombosis (PVT) is a complicated vascular condition resulting from genetic, metabolic, and environmental risk factors. This review underlines current evidence on PVT pathogenesis, clinical management, and emerging therapeutic strategies. Multiple causes of PVT include liver cirrhosis, hepatocellular carcinoma, intra-abdominal infections, and systemic hypercoagulable states, including COVID-19-related thrombosis. Diagnostic challenges persist due to asymptomatic presentations and overlapping imaging findings with other conditions; however, advancements in imaging have improved detection and risk stratification. Anticoagulants remain the cornerstone of treatment, and surgical interventions are reserved for non-responders. Prognosis is influenced by underlying liver disease, thrombus extent, and timely intervention, with cirrhotic PVT linked to higher mortality. Emerging therapies, including miRNA-modified stem cells and radiotherapy for tumor thrombi, show promise but require further validation. Future research must address gaps in genetic predisposition, optimized DOAC dosing in advanced cirrhosis, and the role of gut microbiota in thrombogenesis. This review highlights the importance of personalized, multidisciplinary approaches to enhance outcomes in this clinically diverse condition.

Keywords: Portal Vein Thrombosis (PVT); Hypercoagulability; Oral Anticoagulants (DOACs); Biomarkers; Gut-Liver Axis; Thrombolytic Therapy

Introduction

Portal vein thrombosis (PVT) is a noteworthy vascular disorder marked by the development of a blood clot in the portal vein and its branches, extending up to the splenic vein (SV) and superior mesenteric vein (SMV) [1,2]. It is characterized by partial or complete obstruction of the portal vein, which supplies 3/4th blood to the liver. This obstruction results in compromised hepatic perfusion, potential liver dysfunction and gastrointestinal bleeding [3-5]. This condition is also associated with severe complications such as increased portal venous pressure, variceal bleeding, intestinal ischemia, and liver failure, significantly impacting survival and prognosis [6]. PVT also presents significant challenges in liver transplantation, increasing both perioperative risks and technical difficulties. It is most commonly seen in patients with liver cirrhosis, where it often results from portal hypertension, making individuals susceptible to complications like acute esophageal variceal bleeding [7]. In non-cirrhotic cases, PVT often stems from portal and splenic vein thrombosis, leading to variceal bleeding and splenomegaly [8]. PVT is also associated with malignancies, inflammatory conditions, and myeloproliferative neoplasms (MPNs), broadening its clinical context [9,10]. In neonates, PVT is typically asymptomatic and often remains undiagnosed during this early stage of life [11]. Neonatal PVT is recognized as a key factor in the development of portal hypertension [11]. PVT is frequently asymptomatic and often discovered incidentally during routine imaging, particularly during the surveillance of hepatocellular carcinoma (HCC) or during hospitalization due to complications related to portal hypertension, such as esophageal variceal bleeding [12]. In cirrhosis, PVT serves as a marker of disease severity and is associated with worsened liver function, portal hypertension, and complications such as esophagogastric varices and ascites [13-15]. PVT is often asymptomatic and typically detected incidentally during routine surveillance imaging of hepatocellular carcinoma (HCC) or hospitalization due to complications of portal hypertension [12]. Diagnostic tools such as Doppler ultrasonography are crucial for confirming the diagnosis, as they offer high sensitivity for detecting portal vein occlusion [16]. A holistic overview of Portal Vein Thrombosis (PVT) for clinical research reference and descried in (Figure 1), followed by details sections below:

Epidemiological Burden

PVT is especially prevalent among patients with advanced liver disease, especially cirrhosis and HCC, with rates ranging from 5% to 26% among those with cirrhosis and up to 40% in HCC cases. The prevalence ranges between 0.6% and 16% among patients with compensated cirrhosis. [17-23]. Meta- analyses suggest a pooled prevalence of around 14%, although this figure varies depending on the population and diagnostic techniques used [24-26]. The neonatal intensive care units (NICU) patients are at higher risk for developing PVT [27]. The incidence of neonatal PVT varies widely, ranging from 1.3% to 43% [27]. Studies also indicate that the incidence of PVT increases in more advanced stages of cirrhosis, with annual rates ranging from 3% to 25%. [28]. PVT is considered rare in the population without chronic liver disease, with an incidence of 2-4 per 100,000 individuals [29]. Studies have shown that PVT is responsible for 5% to 10% of all portal hypertension cases in developed countries, while in developing nations, it accounts for up to 33% of cases [8,30,31]. Autopsy studies indicate a prevalence of PVT between 6% to 64%, while studies based on ultrasound report percentages between 5% and 24% [32]. Remove this reference [25,33].

Pathophysiological Insights

The development of PVT is a complex, multifactorial process involving Virchow’s Triad [17,34,35]. In cirrhotic patients, the primary contributors are decreased portal blood flow, elevated intrahepatic vascular resistance, along with increased factor VIII levels and diminished protein C levels [18,36]. The reduction in portal blood flow is particularly pronounced in patients with advanced cirrhosis (Child- Pugh class C) compared to those with milder forms of the disease (Child-Pugh A/B) [37,38]. Genetic factors and systemic conditions, such as endotoxemia, further increase the thrombotic risk [18]. The pathophysiology of cirrhosis involves complex hemostatic alterations due to liver synthetic dysfunction, portal hypertension, and endothelial activation [39]. The mechanism of PVT in cirrhosis is distinct from other thrombotic conditions, such as deep vein thrombosis (DVT) or pulmonary embolism (PE) [16,40]. Unlike the thrombi found in DVT or PE, which primarily consist of fibrin, platelets, and red blood cells, portal vein thrombi are mainly composed of intimal hyperplasia [41,42]. This suggests that terms like “portal vein obstruction” or “portal vein stenosis” may be more appropriate in describing PVT in cirrhosis [16,43]. Further contributing factors to PVT include portal hypertension, endothelial injury, the presence of esophageal varices, and a history of variceal endoscopic treatments [32]. The prothrombotic nature of PVT is also linked to the involvement of neutrophil extracellular traps (NETs), which promote clot formation. NETs, composed of DNA and histones, provide a scaffold for thrombus development and possess strong procoagulant activity [44-46]. Additionally, propranolol, a nonselective β-blocker (NSBB) commonly used in cirrhosis management, has been shown to enhance NET formation by increasing the production of reactive oxygen species (ROS) and NADPH oxidase activity [47,48]. This highlights the paradoxical role of NSBBs in potentially contributing to PVT despite their effectiveness in reducing variceal bleeding [38].

Classification of PVT

“PVT can be classified into cirrhotic PVT, malignant thrombosis, and non-malignant-non-cirrhotic PVT.” [35]. This line provides a basic classification framework for PVT, which is essential in understanding its different types based on etiology (detail given in Table 1) [49-54].

Note: Portal Vein Thrombosis (PVT). Virchow’s triad* (hypercoagulability, endothelial injury, stasis)

Etiological Factors and Risk Contributors

PVT can arise from various etiological factors, encompassing both inherited and acquired conditions. These factors disrupt normal blood flow and lead to thrombogenesis in the portal venous system. The primary causes of PVT include liver diseases (such as cirrhosis and non- alcoholic steatohepatitis), infections, abdominal surgeries, and systemic inflammatory states. Other etiological factors include:

Schistosomiasis-Induced PVT

The pathophysiology of PVT in schistosomiasis is associated with chronic pelvic adhesions and inflammation, which contribute to thrombogenesis [55]. Risk factors for schistosomiasis-induced PVT include cirrhosis, systemic inflammation, reduced portal vein velocity (PVV), wider portal vein diameter (PVD), and the presence of gastroesophageal varices (GOV) [16,56,57].

Intra-abdominal Infections

Intra-abdominal infections are significant contributors to PVT, with pylephlebitis (suppurative thrombophlebitis of the portal vein) being a key complication. Conditions such as appendicitis, diverticulitis, inflammatory bowel disease (IBD), cholecystitis, and pancreatitis have been implicated in the development of PVT. Among these, diverticulitis is a notable risk factor, with an incidence of approximately 3% in colonic diverticulitis [58-67].

COVID-19 and Thrombosis

The hypercoagulable state induced by COVID-19 significantly increases the risk of thrombosis, including PVT and mesenteric vein thrombosis. COVID-19 induces a cytokine storm and endothelial dysfunction, both of which promote thrombosis in unusual sites [68]. Vaccine-induced immune thrombotic thrombocytopenia (VITT), which has been associated with the COVID-19 vaccines, can sometimes result in thrombosis within weeks of vaccination [69].

Systemic infections and Thrombosis

Systemic Infection associated inflammatory responses can lead to a hypercoagulable state, thereby increasing the risk of venous thromboembolism (VTE), including PVT. Infections such as acute toxoplasmosis and bacterial infections with hypervirulent strains of Klebsiella pneumoniae contribute to thrombosis formation through inflammatory mediators and disseminated intravascular coagulation (DIC) [70-75].

Inflammatory Bowel Disease (IBD)

Patients with IBD, particularly those with ulcerative colitis (UC) and Crohn’s disease (CD), have a significantly higher risk of developing PVT and other VTE-related conditions. A nationwide study has shown a 20% increase in VTE-related hospitalizations among IBD patients, with UC linked to an elevated risk of thrombosis [76,77]. This underscores the need for preventive strategies in IBD patients to reduce thrombosis risk.

Cirrhosis and Liver Dysfunction

Cirrhotic patients are in a hypercoagulable state due to elevated von Willebrand factor (vWF) and reduced ADAMTS-13, leading to platelet aggregation and thrombus formation [78]. Factor VIII and deficiencies in Protein C and S also contribute to increased thrombin generation and PVT risk [79-81]. The presence of cirrhosis complicates the diagnosis of PVT, with debates surrounding its role in exacerbating cirrhosis progression or merely reflecting disease severity [82].

Liver Hypoplasia

Liver hypoplasia, a rare condition leading to elevated intrahepatic portal venous pressure, can contribute to PVT. This is particularly relevant for diagnosis in patients undergoing liver transplantation or other surgical procedures [83-85].

Clomiphene Citrate Use

Clomiphene citrate (CC), a drug commonly used for ovulation induction and male infertility treatment, has been associated with an increased risk of thrombosis, including PVT and splanchnic vein thrombosis (SMVT). The drug’s effect on hormonal levels and coagulation pathways may increase the likelihood of venous thromboembolism. Clinical case studies have demonstrated that patients using clomiphene, with no other apparent risk factors, developed PVT and SMVT, suggesting a potential causative role of the medication [86-88].

Metabolic Comorbidities

Patients with non-alcoholic fatty liver disease (NAFLD) are at an elevated risk for developing PVT due to associated metabolic comorbidities such as obesity, type 2 diabetes, and dyslipidemia [89]. Additionally, individuals with COVID-19, particularly those with severe disease or elevated D-dimer and lactate dehydrogenase (LDH) levels, have been found to have an increased incidence of thromboembolic events, including PVT [90,91].

Genetic Factors

Genetic predispositions significantly influence the risk of PVT. Mutations such as Factor V Leiden and prothrombin G20210A have been implicated in increasing thrombotic risk in affected individuals [92,93]. Additionally, the MTHFR TT genotype is associated with an earlier onset of PVT due to elevated homocysteine (HC) levels, which contribute to oxidative damage and thrombosis [94,95].

Hypercoagulable States

Hypercoagulability during pregnancy significantly increases the risk of PVT, especially when compounded by obesity (BMI >30 kg/ m²). Pregnancy-induced changes, such as increased coagulation activity after 28 weeks of gestation, contribute to a heightened thromboembolic risk [96-99].

Risk Factors for Portal Vein Thrombosis

Myeloproliferative Neoplasms and Thrombophilia Clonal hematopoiesis in myeloproliferative neoplasms (MPNs) like polycythemia vera and essential thrombocythemia significantly raises thrombotic risks, including splanchnic vein thrombosis. The JAK2V617F mutation is particularly linked to PVT [9,100,101]. Thrombophilic disorders and low ADAMTS13 activity further exacerbate thrombotic tendencies [16,102].

Post-Surgical and Environmental Risks

PVT has been documented following bariatric surgeries such as sleeve gastrectomy, where the incidence reaches 0.5%, attributable to hypercoagulability and inflammation [103]. Splenectomy, often performed to manage portal hypertension, is another notable risk factor, with PVT incidence rates post-surgery ranging between 18.9% and 57% [104,105].

Metabolic and Virological Factors

Metabolic conditions, including advanced cirrhosis and virological diseases like hepatitis B, heighten PVT risk. Hepatic tuberculosis, though rare, can directly affect the portal vein, leading to thrombosis [106,107]. Sustained virological response via direct-acting antivirals reduces hypercoagulability in cirrhotic patients but does not entirely eliminate the risk in advanced cases [108].

Risk Factors in Neonates

The placement of umbilical venous catheters (UVCs) in neonates has been identified as a significant risk factor for PVT. This triggers bacterial dissemination, which activates the coagulation cascade and leads to thrombus formation [109,110]. Malpositioned UVCs contribute to vessel wall irritation and clot formation. Studies have demonstrated that a notable proportion of neonates with UVCs develop PVT, and prolonged follow-up is essential for children with this risk factor [111,112].

Cancer-Related Risk Factors

Hepatocellular carcinoma (HCC) and cirrhosis contribute significantly to the development of PVT due to a combination of tumor-induced hypercoagulability, liver inflammation, and altered coagulation dynamics. Tumor-induced cytokine release, platelet activation, and extracellular matrix remodeling further promote thrombosis [113- 116]. Additionally, cancer stem cells, particularly those expressing EpCAM and CD133, are linked to PVT and metastasis [117,118].

Other Risk Factors

Alterations in gut microbiota, such as reduced Bacteroides abundance, have been linked to PVT progression in cirrhotic patients, with interventions aimed at restoring the microbiota showing promise in improving outcomes [119]. Additional risk factors for PVT include older age, splenomegaly, ascites, elevated INR, low albumin levels, and high MELD scores [120-122].

Biomarkers and Molecular Predictors

The identification of reliable biomarkers for predicting portal vein thrombosis (PVT) is essential for early detection, risk stratification, and monitoring disease progression. Several clinical and laboratory biomarkers have shown promise in aiding the diagnosis and prognosis of PVT in various patient populations (detail given in Table 2) [123-131].

Note: Von Willebrand Factor (VWF)^#

Diagnostic Approaches

Accurate and timely diagnosis of PVT is crucial for appropriate clinical management. Several diagnostic techniques are employed to detect PVT and assess its severity, with imaging modalities playing a central role in confirming the diagnosis. These techniques include ultrasound, contrast-enhanced imaging (CT and MRI), and advanced diagnostic methods that help identify thrombus presence, associated complications, and underlying conditions such as cirrhosis or malignancy (detail given in Table 3) and diagnostic challenges in Portal Vein Thrombosis have been described in Supplementary Table 1 [132-146].

Note: Portal vein thrombosis (PVT) presents significant diagnostic challenges, primarily due to its often asymptomatic nature, the diversity of its clinical presentations, and its overlap with other conditions. Below listed are the factors that complicate the identification of PVT.

Initial Management Strategies

The management of PVT involves a comprehensive approach tailored to the underlying cause, severity, and patient-specific factors. Initial treatment typically includes rapid anticoagulation with Low Molecular Weight Heparin (LMWH) or unfractionated heparin, followed by a prolonged course (≥6 months) to prevent thrombus progression. Once stabilized, patient is transitioned to oral anticoagulants like warfarin (target INR: 2–3) or direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, or dabigatran [65,147-151]. DOACs often preferred due to their safety profile and ease of use. In cases where anticoagulation fails or is contraindicated, interventions like Trans-jugular Intrahepatic Portosystemic Shunt (TIPS) or surgical thrombectomy may be necessary. Adjunct therapies such as endoscopic variceal ligation and beta blockers are essential for preventing variceal bleeding [152-158] (detail given in Table 4) [159-192].

Prognosis and Outcome Predictors

Impact of Anticoagulation and Underlying Conditions

The prognosis of PVT is majorly influenced by the timely initiation of anticoagulation therapy and management of underlying conditions. In cirrhotic patients without anticoagulation therapy, approximately 22% experience progression of PVT, while 77.7% have stable or improved conditions. Notably, 29.3% of cases experience regression of PVT, but complete recanalization occurs in only 10.4%, and recurrence is observed in 24% of patients [193].

Effect of Liver Disease and Coexisting Conditions

The underlying liver disease is a key factor in determining prognosis. Cirrhotic patients with PVT experience a significant decrease in two-year survival rates, primarily due to impaired liver function and associated complications [194]. In contrast, patients with non-alcoholic fatty liver disease (NAFLD) related PVT generally have a better prognosis when treated with anticoagulation therapy. The NAFLD patients showed complete recanalization within six months without long-term complications with the use of edoxaban to prevent recurrence [195]. Factors such as a higher MELD score and the presence of ascites are linked to worse outcomes in cirrhotic patients with PVT [193]. For non-cirrhotic, non- malignant PVT, the 1-year mortality rate is lower (8%) compared to malignancy- or cirrhosis- associated PVT, which has a higher 1-year mortality rate (~26%) [196].

Acute PVT with Intestinal Ischemia

Acute PVT complicated by intestinal ischemia has a particularly poor prognosis, with mortality rates ranging from 20% to 50% [30,197]. Early intervention and anticoagulation therapy can improve survival rates in these cases, highlighting the importance of prompt diagnosis and management.

PVT and Venous Thromboembolism (VTE)

PVT is strongly associated with venous thromboembolism (VTE), including pulmonary embolism (PE), with an increased risk of VTE in PVT patients, particularly in those with idiopathic PVT [198]. The risk of PE is concerning due to its high mortality rates, especially when associated with cardiac arrest, as 70% of fatal cardiac arrests occur within the first hour of PE onset [199,200]. Therefore, early preventive measures and monitoring for VTE and PE in PVT patients are critical to improving prognosis.

Prophylaxis and Long-Term Monitoring

For cirrhotic patients, prophylactic anticoagulation therapy may decrease the incidence of PVT and improve long-term outcomes [201]. Long-term anticoagulation therapy has been shown to reduce the frequency of variceal bleeding episodes, improve outcomes by lowering microvascular thrombosis, and reduce portal vein pressure [202]. However, patients with cirrhosis and low platelet counts (below 50,000/mL) may be at higher risk for bleeding, with major bleeding rates reaching up to 9% [150,203].

Extrahepatic Portal Vein Obstruction (EHPVO)

In patients with Extrahepatic Portal Vein Obstruction (EHPVO), long-term survival can be improved with individualized care, including primary and secondary prophylaxis for variceal bleeding [140]. Proximal splenorenal shunts offer an 80% survival rate, while Rex surgery boasts nearly 100% long-term survival [140]. Post-surgical monitoring is critical to detect complications such as variceal recurrence and portosystemic encephalopathy.

Vascular Invasion in Hepatocellular Carcinoma (HCC)

Vascular invasion, particularly in HCC with PVT, significantly impacts survival. Patients with vascular invasion (Vp1-Vp4) exhibit progressively worse survival rates, with Child-Pugh A patients undergoing hepatic resection showing median survival rates of 34 months [204]. Survival decreases as the degree of vascular invasion increases (Vp1: 42.7%, Vp2: 25.2%, Vp3: 22.3%, Vp4: 9.8%) [204].

Pylephlebitis and Long-Term Monitoring

Pylephlebitis, when left untreated, can lead to severe complications such as hepatic abscess, mesenteric ischemia, portal hypertension, and pulmonary embolism, which significantly worsen prognosis. Regular follow-up imaging is essential to monitor thrombus resolution and prevent complications [63,205]. Aggressive management, including anticoagulation and long-term monitoring, is critical for improving patient outcomes and reducing morbidity and mortality associated with this condition [148].

Portal Hypertension (PHT)

Portal hypertension plays a crucial role in the prognosis of PVTT, exacerbating complications such as refractory ascites and esophagogastric varices, which can lead to gastrointestinal bleeding. Managing PHT through interventions like portal vein stenting and radiofrequency ablation (RFA) can improve survival outcomes in PVTT patients by reducing the risk of bleeding and worsening liver dysfunction [206].

Survival and Prognostic Indicators in PVT

Survival in PVT is significantly influenced by the extent of thrombosis and the presence of vascular invasion, with survival times being particularly short when the main portal vein is involved (MPVTT). Median survival in such cases ranges from 2.7 to 4 months [185,207,208]. This highlights the importance of early detection, aggressive management, and personalized treatment strategies to improve prognosis, especially in high-risk patients.

Complications and Clinical Challenges

Variceal Re-Hemorrhage

Chronic PVT significantly heightens the risk of variceal re-hemorrhage [209]. Patients with cirrhosis and cavernous transformation of the portal vein generally have better outcomes, including lower mortality rates, compared to those without cavernous transformation [210]. A recent study revealed that TIPS is more effective than anticoagulation alone in achieving portal vein recanalization and improving survival, with reduced rates of variceal rebleeding and refractory ascites in the TIPS group [211].

Portal Hypertension and Its Effects

Portal hypertension in PVT can lead to the development of varices, splenomegaly, and hypersplenism, all of which require careful management [212,213].

Extrahepatic Portal Vein Obstruction (EHPVO)

In patients with Extrahepatic Portal Vein Obstruction (EHPVO), variceal bleeding, particularly from ectopic varices, is a significant clinical challenge [214,215].

Septicemia and Bacterial Translocation

A rare but serious complication in PVT patients is Clostridium paraputrificum septicemia, typically observed in immunocompromised individuals or those with gastrointestinal pathology [216,217]. In cases of ischemic bowel disease, the disruption of the mucosal barrier facilitates bacterial translocation into the bloodstream [218]. The introduction of MALDI-TOF mass spectrometry has enhanced the detection of anaerobic infections, improving diagnostic accuracy in these cases [219,220].

Complications in Neonates

In neonates, long-term complications of PVT include liver lobe atrophy, splenomegaly, and portal hypertension, necessitating ongoing monitoring [27].

Future Direction and Research Gap

Further investigation is needed to explore the role of coagulation markers and portal vein velocity in identifying cirrhotic patients at risk for PVT, especially in those who achieve sustained virological response (SVR) [42,221,222]. Focused research into diagnostic advancements, targeted therapies, and optimized anticoagulation protocols is essential to improve outcomes in PVT management [42]. Additionally, the potential role of NSBBs in promoting PVT via NETs and neutrophil activity in cirrhosis warrants further exploration [42,221,222]. Similarly, future studies should also investigate the mechanisms behind clomiphene-associated thrombosis and enhance management strategies for cirrhotic PVT and drug-related thromboembolic events. The limitations of current studies include small sample sizes, which affect the generalizability of findings. The absence of comparison across different disease stages restricts insights into how disease progression influences treatment outcomes. The retrospective nature of many studies and single-center settings introduce potential biases. To address these issues, future prospective clinical trials with larger, multicenter populations are needed to validate findings, biomarkers, optimize thrombolytic regimens, and explore the role of gut-liver interactions in PVT development along with the efficacy of combined therapies for PVTT in HCC [102,131,159,206].

Research into miRNA-modified human umbilical cord-derived mesenchymal stem cells (hucMSCs) holds promise for endothelial repair and vascular health [173,174]. Future studies should explore the molecular mechanisms behind miRNA-modified therapies and their broader applications in vascular diseases [180,181]. Similarly, genetic predisposition, especially MTHFR genotypes, highlights the need for early screening and personalized therapies for PVT [94,95]. While radiotherapy, including stereotactic radiotherapy (SRT) and hypo-fractionated radiotherapy, shows potential for managing PVTT in HCC, challenges remain in determining the optimal radiation dose and fractionation schedule for external beam radiotherapy (EBRT) and SRT. Further studies are necessary to establish the best anticoagulation regimens and minimize side effects to improve therapeutic outcomes for PVT.

Conclusion

PVT is a complex thrombotic condition influenced by a range of genetic, metabolic, and environmental risk factors. Key contributors include hormonal therapies like clomiphene citrate, underlying comorbidities such as obesity and NAFLD, genetic predispositions, and surgical procedures. Additionally, cancer, particularly HCC, liver cirrhosis, infections, and mechanical factors such as bariatric surgery, play significant roles in the pathogenesis of PVT. Advances in the understanding of infections, gut microbiota, micro-vesicles, and cancer stem cells offer opportunities to improve diagnostic tools and therapeutic strategies, thereby reducing thrombotic risk and enhancing patient outcomes [154,223,224]. The treatment of non-cirrhotic PVT (NCPVT) primarily includes anticoagulation therapy, with direct oral anticoagulants (DOACs) becoming the preferred choice due to their safety and convenience [154]. Endovascular interventions are increasingly utilized in refractory cases, while careful management of portal hypertensive complications remains essential, especially in chronic PVT [223,224]. The complex and multifactorial nature of PVT demands a thorough and individualized approach to diagnosis and treatment. Ongoing research is needed to better understand the molecular basis of PVT, refine management strategies, and develop predictive models to improve patient outcomes. The development of more effective therapies, coupled with early detection and intervention, will be key to addressing the challenges posed by PVT in both cirrhotic and non-cirrhotic patients [59].

Funding

No funding was available.

Conflict of Interest

No.

References

1. De Stefano V, Martinelli I (2010) Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 5(6): 487-494.
2. Valla DC, Condat B (2000) Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol 32(5): 865-871.
3. Martin A, Struble S, Prado A, Robinson J, Goddard J, et al. (2022) A Case of Portal Vein Thrombosis in a Patient With Methylenetetrahydrofolate Reductase A1298C Polymorphism. Cureus 14(1): e21743.
4. Manzano-Robleda Mdel C, Barranco-Fragoso B, Uribe M, Mendez-Sanchez N (2015) Portal vein thrombosis: what is new? Ann Hepatol 14(1): 20-27.
5. Gioia S, Nardelli S, Ridola L, Riggio O (2020) Causes and Management of Non-cirrhotic Portal Hypertension. Curr Gastroenterol Rep 22(12): 56.
6. Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, et al. (2015) Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. World J Hepatol 7(27): 2774-2780.
7. (2016) In: Acute upper gastrointestinal bleeding in over 16s: management. edn. London.
8. Valla DC, Condat B, Lebrec D (2002) Spectrum of portal vein thrombosis in the West. J Gastroenterol Hepatol 17(Suppl 3): S224-S227.
9. Tremblay D, Winters A, Beckman JD, Naymagon L, Patel R, et al. (2022) Splanchnic vein thrombosis associated with myeloproliferative neoplasms. Thromb Res 218: 8-16.
10. Alvarez-Larran A, Pereira A, Magaz M, Hernandez-Boluda JC, Garrote M, et al. (2020) Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. Ann Hematol 99(4): 791-798.
11. Williams S, Chan AK (2011) Neonatal portal vein thrombosis: diagnosis and management. Semin Fetal Neonatal Med 16(6): 329-339.
12. Allaire M, Thabut D (2024) Reply: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management. Hepatology 79(1): E3.
13. Yoshida H, Shimizu T, Yoshioka M, Taniai N (2021) Management of portal hypertension based on portal hemodynamics. Hepatol Res 51(3): 251-262.
14. Tadokoro T, Morishita A, Masaki T (2021) Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. Int J Mol Sci 22(15).
15. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, et al. (2004) Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 40(5): 736-741.
16. Turon F, Driever EG, Baiges A, Cerda E, Garcia-Criado A, et al. (2021) Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol 75(6): 1367-1376.
17. Costache RS, Dragomirica AS, Dumitras EA, Mariana J, Caruntu A, et al. (2021) ortal vein thrombosis: A concise review (Review). Exp Ther Med 22(1): 759.
18. Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN (2018) Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 31(3): 315-329.
19. Luo X, Wang W, Fan X, Zhao Y, Wang X, et al. (2018) Short-Term Outcome of Patients with Cirrhosis and Concurrent Portal Cavernoma Presenting with Acute Variceal Bleeding. Can J Gastroenterol Hepatol 2018: 9491856.
20. Urhut MC, Sandulescu LD, Ciocalteu A, Cazacu SM, Danoiu S (2023) The Clinical Value of Multimodal Ultrasound for the Differential Diagnosis of Hepatocellular Carcinoma from Other Liver Tumors in Relation to Histopathology. Diagnostics (Basel) 13(20).
21. Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, et al. (2018) Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 118(8): 1491-1506.
22. Ponziani FR, Zocco MA, Garcovich M, D'Aversa F, Roccarina D, et al. (2012) What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. World J Gastroenterol 18(36): 5014-5020.
23. Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, et al. (2019) Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 25(31): 4360-4382.
24. Pan J, Wang L, Gao F, An Y, Yin Y, et al. (2022) Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med 104: 21-32.
25. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK (2010) Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 31(3): 366-374.
26. Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, et al. (2015) Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 61(2): 660-667.
27. Morag I, Epelman M, Daneman A, Moineddin R, Parvez B, et al. (2006) Portal vein thrombosis in the neonate: risk factors, course, and outcome. J Pediatr 148(6): 735-739.
28. Senzolo M, Garcia-Tsao G, Garcia-Pagan JC (2021) Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol 75(2): 442-453.
29. Ageno W, Dentali F, Pomero F, Fenoglio L, Squizzato A, et al. (2017) Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost 117(4): 794-800.
30. Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora AD, et al. (2010) Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol 16(2): 143-155.
31. Prakash S, Bies J, Hassan M, Mares A, Didia SC (2023) Portal vein thrombosis in cirrhosis: A literature review. Front Med (Lausanne) 10: 1134801.
32. Fimognari FL, Violi F (2008) Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 3(3): 213-218.
33. Francoz C, Valla D, Durand F (2012) Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 57(1): 203-212.
34. Hoekstra J, Janssen HL (2009) Vascular liver disorders (II): portal vein thrombosis. Neth J Med 67(2): 46-53.
35. Trebicka J, Strassburg CP (2014) Etiology and Complications of Portal Vein Thrombosis. Viszeralmedizin 30(6): 375-380.
36. Kumar A, Sharma P, Arora A (2015) Review article: portal vein obstruction--epidemiology, pathogenesis, natural history, prognosis and treatment. Aliment Pharmacol Ther 41(3): 276-292.
37. Arroyo AB, Fernandez-Perez MP, Del Monte A, Aguila S, Mendez R, et al. (2021) miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. Haematologica 106(6): 1636-1646.
38. Noubouossie DF, Reeves BN, Strahl BD, Key NS (2019) Neutrophils: back in the thrombosis spotlight. Blood 133(20): 2186-2197.
39. Lisman T, Hernandez-Gea V, Magnusson M, Roberts L, Stanworth S, et al. (2021) The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost 19(4): 1116-1122.
40. Scheiner B, Northup PG, Gruber AB, Semmler G, Leitner G, et al. (2020) The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Liver Int 40(6): 1415-1426.
41. Chernysh IN, Nagaswami C, Kosolapova S, Peshkova AD, Cuker A, et al. (2020) The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep 10(1): 5112.
42. Driever EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, van den Heuvel MC, et al. (2022) Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology 75(4): 898-911.
43. Harskamp RE, Lopes RD, Baisden CE, de Winter RJ, Alexander JH (2013) Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann Surg 257(5): 824-833.
44. Gunther R, Folsch UR (2002) [High plasma levels of factor VIII and von Willebrand factor in a patient with portal vein thrombosis]. Z Gastroenterol 40(6): 409-412.
45. Afif AM, Chang JP, Wang YY, Lau SD, Deng F, et al. (2017) A sonographic Doppler study of the hepatic vein, portal vein and hepatic artery in liver cirrhosis: Correlation of hepatic hemodynamics with clinical Child Pugh score in Singapore. Ultrasound 25(4): 213-221.
46. Zekanovic D, Ljubicic N, Boban M, Nikolic M, Delic-Brkljacic D, et al. (2010) Doppler ultrasound of hepatic and system hemodynamics in patients with alcoholic liver cirrhosis. Dig Dis Sci 55(2): 458-466.
47. Wang L, Guo X, Bai Z, Yin Y, Xu S, et al. (2022) Impact of Asymptomatic Superior Mesenteric Vein Thrombosis on the Outcomes of Patients with Liver Cirrhosis. Thromb Haemost 122(12): 2019-2029.
48. Marx I, Christophe OD, Lenting PJ, Rupin A, Vallez MO, et al. (2008) Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 112(3): 603-609.
49. Pieri G, Theocharidou E, Burroughs AK (2013) Liver in haematological disorders. Best Pract Res Clin Gastroenterol 27(4): 513-530.
50. Kinjo N, Kawanaka H, Akahoshi T, Matsumoto Y, Kamori M, et al. (2014) Portal vein thrombosis in liver cirrhosis. World J Hepatol 6(2): 64-71.
51. Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE (2010) Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 8(2): 200-205.
52. Acosta S, Alhadad A, Svensson P, Ekberg O (2008) Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg 95(10): 1245-1251.
53. Webster GJ, Burroughs AK, Riordan SM (2005) Review article: portal vein thrombosis -- new insights into aetiology and management. Aliment Pharmacol Ther 21(1): 1-9.
54. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, et al. (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25): 4921-4928.
55. Riera M, Buczacki S, Khan ZA (2009) Splenic regeneration following splenectomy and impact on sepsis: a clinical review. J R Soc Med 102(4): 139-142.
56. Stine JG, Wang J, Shah PM, Argo CK, Intagliata N, et al. (2018) Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study. Liver Int 38(1): 94-101.
57. Pere G, Basselerie H, Maulat C, Pitocco A, Leblanc P, et al. (2021) Splenic volume and splenic vein diameter are independent pre-operative risk factors of portal vein thrombosis after splenectomy: a retrospective cohort study. BMC Surg 21(1): 366.
58. Maejima T, Hashimoto E, Hirose K, Miyazaki K, Suzuki M, et al. (2024) Pylephlebitis Secondary to Diverticulitis Diagnosed by Abdominal Ultrasound and Computed Tomography. Cureus 16(11): e73358.
59. Kim C, Torres V, Urayeneza O, Hinika G (2022) Pylephlebitis: A Rare Complication of Acute Appendicitis. Cureus 14(11): e31377.
60. Singh P, Yadav N, Visvalingam V, Indaram A, Bank S (2001) Pylephlebitis--diagnosis and management. Am J Gastroenterol 96(4): 1312-1313.
61. Agha RA, Franchi T, Sohrabi C, Mathew G, Kerwan A, et al. (2020) The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. Int J Surg 84: 226-230.
62. Plemmons RM, Dooley DP, Longfield RN (1995) Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 21(5): 1114-1120.
63. Kanellopoulou T, Alexopoulou A, Theodossiades G, Koskinas J, Archimandritis AJ (2010) Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome. Scand J Infect Dis 42(11-12): 804-811.
64. Nishimori H, Ezoe E, Ura H, Imaizumi H, Meguro M, et al. (2004) Septic thrombophlebitis of the portal and superior mesenteric veins as a complication of appendicitis: report of a case. Surg Today 34(2): 173-176.
65. Choudhry AJ, Baghdadi YM, Amr MA, Alzghari MJ, Jenkins DH, et al. (2016) Pylephlebitis: a Review of 95 Cases. J Gastrointest Surg 20(3): 656-661.
66. Tsao YT, Lin SH, Cheng CJ, Chang FY (2006) Pylephlebitis associated with acute infected choledocholithiasis. Am J Med Sci 332(2): 85-87.
67. Baddley JW, Singh D, Correa P, Persich NJ (1999) Crohn's disease presenting as septic thrombophlebitis of the portal vein (pylephlebitis): case report and review of the literature. Am J Gastroenterol 94(3): 847-849.
68. Inam F, Singh PR, Khalid F, Javed A, Shah AR (2021) Acute Coronary Syndrome and COVID-19: A Case Report of Refractory Hypercoagulability. Cureus 13(3): e13675.
69. Arepally GM, Ortel TL (2021) Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood 138(4): 293-298.
70. Tichelaar YI, Kluin-Nelemans HJ, Meijer K (2012) Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost 107(5): 827-837.
71. Olson NC, Cushman M, Lutsey PL, McClure LA, Judd S, et al. (2014) Inflammation markers and incident venous thromboembolism: the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost 12(12):1993-2001.
72. Fusaro L, Di Bella S, Martingano P, Croce LS, Giuffre M (2023) Pylephlebitis: A Systematic Review on Etiology, Diagnosis, and Treatment of Infective Portal Vein Thrombosis. Diagnostics (Basel) 13(3).
73. Lee HC, Chuang YC, Yu WL, Lee NY, Chang CM, et al. (2006) Clinical implications of hypermucoviscosity phenotype in Klebsiella pneumoniae isolates: association with invasive syndrome in patients with community-acquired bacteraemia. J Intern Med 259(6): 606-614.
74. Yu WL, Ko WC, Cheng KC, Lee HC, Ke DS, et al. (2006) Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect Dis 42(10):1351-1358.
75. Molton JS, Chee YL, Hennedige TP, Venkatesh SK, Archuleta S (2015) Impact of Regional Vein Thrombosis in Patients with Klebsiella pneumoniae Liver Abscess. PLoS One 10(10): e0140129.
76. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, et al. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1): 46-54 e42; quiz e30.
77. Faye AS, Colombel JF (2022) Aging and IBD: A New Challenge for Clinicians and Researchers. Inflamm Bowel Dis 28(1):126-132.
78. Sigal SH, Sherman Z, Jesudian A (2020) Clinical Implications of Thrombocytopenia for the Cirrhotic Patient. Hepat Med 12: 49-60.
79. Senzolo M, Burra P, Cholongitas E, Burroughs AK (2006) New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 12(48): 7725-7736.
80. Jiang S, Ai Y, Fan X, Huang X, Wu L, et al. (2023) Increased Factor VIII Activity Is Predictive of the Occurrence of Portal Vein Thrombosis in Cirrhosis. Thromb Haemost 123(7): 714-722.
81. Depasse F, Binder NB, Mueller J, Wissel T, Schwers S, et al. (2021) Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine. J Thromb Haemost 19(12): 2907-2917.
82. Faccia M, Ainora ME, Ponziani FR, Riccardi L, Garcovich M, et al. (2019) Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. World J Gastroenterol 25(31): 4437-4451.
83. Merrill GG (1946) Complete absence of the left lobe of the liver. Arch Pathol (Chic) 42: 232.
84. Prithishkumar IJ, Kanakasabapathy I (2010) Agenesis of the left lobe of liver - A rare anomaly with associated hepatic arterial variations. Clin Anat 23(8): 899-901.
85. Rossi JM, Dunn NR, Hogan BL, Zaret KS (2001) Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. Genes Dev 15(15): 1998-2009.
86. Glueck CJ, Wang P (2014) Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism 63(8): 989-994.
87. Benshushan A, Shushan A, Paltiel O, Mordel N, Laufer N (1995) Ovulation induction with clomiphene citrate complicated by deep vein thrombosis. Eur J Obstet Gynecol Reprod Biol 62(2): 261-262.
88. Solipuram V, Pokharel K, Ihedinmah T (2021) Pulmonary Embolism as a Rare Complication of Clomiphene Therapy: A Case Report and Literature Review. Case Rep Endocrinol 2021: 9987830.
89. Li J, Wang Q, Yang M, Sun X (2022) Metabolic Disorders and Risk of Portal Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Turk J Gastroenterol 33(7): 541-553.
90. Gong X, Yuan B, Yuan Y (2022) Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis. PLoS One 17(3): e0263580.
91. Lobbes H, Mainbourg S, Mai V, Douplat M, Provencher S, et al. (2021) Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. Int J Environ Res Public Health 18(24).
92. Hally K, Fauteux-Daniel S, Hamzeh-Cognasse H, Larsen P, Cognasse F (2020) Revisiting Platelets and Toll-Like Receptors (TLRs): At the Interface of Vascular Immunity and Thrombosis. Int J Mol Sci 21(17).
93. Duttaroy AK (2021) Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review. Nutrients 13(1).
94. Qi X, Yang Z, De Stefano V, Fan D (2014) Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis of observational studies. Hepatol Res 44(14): E480-498.
95. Wu C, Lu W, Zhang Y, Zhang G, Shi X, et al. (2019) Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis. Immunity 50(6):1401-1411 e1404.
96. Hoekstra J, Seijo S, Rautou PE, Ducarme G, Boudaoud L, et al. (2012) Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome. J Hepatol 57(6): 1214-1219.
97. Hosomi S, Oyama R, Isurugi C, Sato T, Baba T (2024) Pregnancy Complicated by Extrahepatic Portal Vein Occlusion and Portal Vein Thrombosis: A Case Report. Cureus 16(10): e72457.
98. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, et al. (2009) Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 20(11): 1431-1440.
99. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, et al. (2012) Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl): e278S-e325S.
100. Perner F, Perner C, Ernst T, Heidel FH (2019) Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells 8(8).
101. Vannucchi AM, Guglielmelli P (2013) JAK2 mutation-related disease and thrombosis. Semin Thromb Hemost 39(5): 496-506.
102. Lancellotti S, Basso M, Veca V, Sacco M, Riccardi L, et al. (2016) Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Intern Emerg Med 11(7): 959-967.
103. Giannis D, Geropoulos G, Kakos CD, Lu W, El Hadwe S, et al. (2023) Portomesenteric Vein Thrombosis in Patients Undergoing Sleeve Gastrectomy: an Updated Systematic Review and Meta-Analysis of 101,914 Patients. Obes Surg 33(10): 2991-3007.
104. Intagliata NM, Caldwell SH, Tripodi A (2019) Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 156(6):1582-1599 e1581.
105. Ushitora Y, Tashiro H, Takahashi S, Amano H, Oshita A, et al. (2011) Splenectomy in chronic hepatic disorders: portal vein thrombosis and improvement of liver function. Dig Surg 28(1): 9-14.
106. Ghossein RA, Ross DG, Salomon RN, Rabson AR (1992) Rapid detection and species identification of mycobacteria in paraffin-embedded tissues by polymerase chain reaction. Diagn Mol Pathol 1(3):185-191.
107. Zheng SM, Lin N, Tang SH, Yang JY, Wang HQ, et al. (2021) Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: A case report and review of the literature. World J Clin Cases 9(30): 9310-9319.
108. Mandorfer M, Turon F, Lens S, Baiges A, Garcia-Criado A, et al. (2021) Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. Liver Int 41(12): 2954-2964.
109. Bhatt MD, Chan AK (2021) Venous thrombosis in neonates. Fac Rev 10: 20.
110. Gialamprinou D, Mitsiakos G, Katsaras GN, Kontovazainitis CG, Karagianni P, et al. (2022) Neonatal Sepsis and Hemostasis. Diagnostics (Basel) 12(2).
111. Soonsawad S, Kieran EA, Ting JY, AlonsoPrieto E, Panczuk JK (2022) Factors Associated with Umbilical Venous Catheter Malposition in Newborns: A Tertiary Center Experience. Am J Perinatol 39(16): 1805-1811.
112. Cakir SC, Ozkan H, Dorum BA, Koksal N, Kudretoglu P, et al. (2020) The danger awaiting premature babies: Portal vein thrombosis. Turk Pediatri Ars 55(3): 257-262.
113. Galasso L, Cerrito L, Maccauro V, Termite F, Ainora ME, et al. (2024) Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress. Cancers (Basel) 16(10).
114. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, et al. (2003) Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9(14): 5339-5345.
115. Zanetto A, Senzolo M, Campello E, Bulato C, Gavasso S, et al. (2021) Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. Cancers (Basel) 13(5).
116. Zanetto A, Senzolo M, Vitale A, Cillo U, Radu C, et al. (2017) Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 49(4): 440-445.
117. Abdelgawad IA (2020) Epithelial Cell Adhesion Molecule mRNA Can be a Potential Marker to Predict Metastasis in Hepatocellular Carcinoma Patients. Asian Pac J Cancer Prev 21(3): 861-866.
118. Zhong C, Wu JD, Fang MM, Pu LY (2015) Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis. Tumour Biol 36(10): 7623-7630.
119. Huang XY, Zhang YH, Yi SY, Lei L, Ma T, et al. (2023) Potential contribution of the gut microbiota to the development of portal vein thrombosis in liver cirrhosis. Front Microbiol 14: 1217338.
120. Cagin YF, Bilgic Y, Berber I, Yildirim O, Erdogan MA, et al. (2019) The risk factors of portal vein thrombosis in patients with liver cirrhosis. Exp Ther Med 17(4): 3189-3194.
121. Lertpipopmetha K, Auewarakul CU (2011) High incidence of hepatitis B infection-associated cirrhosis and hepatocellular carcinoma in the Southeast Asian patients with portal vein thrombosis. BMC Gastroenterol 11: 66.
122. Maruyama H, Okugawa H, Takahashi M, Yokosuka O (2013) De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol 108(4): 568-574.
123. Lewis CS, Bari K, Xie C, Sherman KE, Vasse M, et al. (2023) Potential utility of a multi-component coagulation factor panel to calculate MELD scores and assess the risk of portal vein thrombosis in chronic liver disease. BMC Gastroenterol 23(1): 65.
124. Nie GL, Yan J, Li Y, Zhang HL, Xie DN, et al. (2024) Predictive model for non-malignant portal vein thrombosis associated with cirrhosis based on inflammatory biomarkers. World J Gastrointest Oncol 16(4): 1213-1226.
125. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, et al. (2019) Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl 25(2): 207-216.
126. Li T, Yu Y, Liu J, Tian X, Kong M, et al. (2019) PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma. Infect Agent Cancer 14: 13.
127. Takaya H, Namisaki T, Asada S, Iwai S, Kubo T, et al. (2022) ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. J Clin Med 11(7).
128. Sacco M, Tardugno M, Lancellotti S, Ferretti A, Ponziani FR, et al. (2022) ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study. Dig Liver Dis 54(12): 1672-1680.
129. Ji F, Fu S, Guo Z, Pang H, Chen D, et al. (2016) Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget 7(44): 72276-72289.
130. Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, et al. (2013) Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol 30(4): 721.
131. Hasan RA, Koh AY, Zia A (2020) The gut microbiome and thromboembolism. Thromb Res 189: 77-87.
132. Koratala A, Reisinger N (2022) Venous Excess Doppler Ultrasound for the Nephrologist: Pearls and Pitfalls. Kidney Med 4(7): 100482.
133. Majid Z, Tahir F, Bin Arif T, Ahmed J (2020) Chronic Non-cirrhotic Portal Vein Thrombosis with Cavernous Transformation Secondary to Protein C and S Deficiency. Cureus 12(2): e7142.
134. Ueno N, Sasaki A, Tomiyama T, Tano S, Kimura K (1997) Color Doppler ultrasonography in the diagnosis of cavernous transformation of the portal vein. J Clin Ultrasound 25(5): 227-233.
135. Grube E, Giesing M (1986) Antihypertensive therapy in the Federal Republic of Germany: clinical practice experience with indoramin (Wydora). J Cardiovasc Pharmacol 8 Suppl 2: S43-47.
136. De Gaetano AM, Lafortune M, Patriquin H, De Franco A, Aubin B, et al. (1995) Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. AJR Am J Roentgenol 165(5): 1151-1155.
137. Qi X, Han G, Bai M, Fan D (2011) Stage of portal vein thrombosis. J Hepatol 54(5):1080-1082.
138. Ricci P, Cantisani V, Biancari F, Drud FM, Coniglio M, et al. (2000) Contrast-enhanced color Doppler US in malignant portal vein thrombosis. Acta Radiol 41(5): 470-473.
139. Sorrentino P, D'Angelo S, Tarantino L, Ferbo U, Bracigliano A, et al. (2009) Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients. World J Gastroenterol 15(18): 2245-2251.
140. Khanna R, Sarin SK (2014) Non-cirrhotic portal hypertension - diagnosis and management. J Hepatol 60(2): 421-441.
141. Shyam VS, Rana S, Vinay Kumar BR, Choudhury A, Mukund A (2022) Suppurative Pylephlebitis With Portal Vein Abscess Mimicking Portal Vein Thrombosis: A Report of Two Cases. J Clin Exp Hepatol 12(1): 208-211.
142. Davarpanah AH, Eberhardt LW (2020) Case 282: Fishbone Pylephlebitis. Radiology 297(1): 239-243.
143. Farin P, Paajanen H, Miettinen P (1997) Intraoperative US diagnosis of pylephlebitis (portal vein thrombosis) as a complication of appendicitis: a case report. Abdom Imaging 22(4): 401-403.
144. Mortele KJ, Segatto E, Ros PR (2004) The infected liver: radiologic-pathologic correlation. Radiographics 24(4): 937-955.
145. Mert A, Ozaras R, Tabak F, Ozturk R, Bilir M (2003) Localized hepatic tuberculosis. Eur J Intern Med 14(8): 511-512.
146. Diaz ML, Herrera T, Lopez-Vidal Y, Calva JJ, Hernandez R, et al. (1996) Polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA in tissue and assessment of its utility in the diagnosis of hepatic granulomas. J Lab Clin Med 127(4): 359-363.
147. Galante A, De Gottardi A (2021) Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg 84(2): 327-332.
148. Trad G, Sheikhan N, Nguyen A, Valenta J, Iraninezhad H (2022) Portal Vein Thrombosis and Pyogenic Liver Abscess With Concomitant Bacteroides Bacteremia in a Patient With COVID-19 Infection: A Case Report and Brief Review. J Investig Med High Impact Case Rep 10: 23247096221084513.
149. Naymagon L, Tremblay D, Schiano T, Mascarenhas J (2020) The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes. J Thromb Thrombolysis 49(2): 325-331.
150. Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, et al. (2012) Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 10(7): 776-783.
151. Gao Z, Li S, Zhao J, Li J, Gao Y (2023) Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial. Intern Emerg Med 18(2): 513-521.
152. Yao W, Feng Y, Liu T, Li W, Zhang M, et al. (2021) Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial. EXCLI J 20: 537-549.
153. Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ (2018) Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. Int J Hepatol 2018: 8432781.
154. Li A, Zhang MC, Li P, Eshaghpour A, Li K, et al. (2023) Direct oral anticoagulants for the treatment of splanchnic vein thrombosis - A systematic review and meta-analysis. Thromb Res 229: 209-218.
155. van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12): 1968-1975.
156. Calcaterra I, Tufano A, Strano F, Rufolo P, Donnarumma S, et al. (2024) Efficacy and safety of direct oral anticoagulants in splanchnic vein thrombosis: a pooled analysis of literature studies. J Thromb Haemost 22(2): 534-544.
157. Han G, Qi X, He C, Yin Z, Wang J, et al. (2011) Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol 54(1): 78-88.
158. Qi X, Han G, Fan D (2014) Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol 11(7): 435-446.
159. Gao F, Wang L, Pan J, Yin Y, Wang J, et al. (2023) Efficacy and safety of thrombolytic therapy for portal venous system thrombosis: A systematic review and meta-analysis. J Intern Med 293(2): 212-227.
160. Ju C, Li X, Gadani S, Kapoor B, Partovi S (2022) Portal Vein Thrombosis: Diagnosis and Endovascular Management. Rofo 194(2): 169-180.
161. Cui SB, Shu RH, Yan SP, Wu H, Chen Y, et al. (2015) Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol 27(8): 914-919.
162. Sharma A, Keshava SN, Eapen A, Elias E, Eapen CE (2021) An Update on the Management of Budd-Chiari Syndrome. Dig Dis Sci 66(6): 1780-1790.
163. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, et al. (2021) Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 73(1): 366-413.
164. de Franchis R, Baveno VF (2010) Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53(4): 762-768.
165. Jevtic D, Gavrancic T, Pantic I, Nordin T, Nordstrom CW, et al. (2022) Suppurative Thrombosis of the Portal Vein (Pylephlebits): A Systematic Review of Literature. J Clin Med 11(17).
166. Yin Y, Wang L, Gao F, Liu L, Qi X (2023) Anticoagulation Therapy for Splanchnic Vein Thrombosis Associated With Acute Pancreatitis: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost 29: 10760296231188718.
167. Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, et al. (2006) Consensus on extra-hepatic portal vein obstruction. Liver Int 26(5): 512-519.
168. Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, et al. (2020) The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv 4(4): 655-666.
169. Tang N, Bai H, Chen X, Gong J, Li D, et al. (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5): 1094-1099.
170. Martin K, Key NS (2016) How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 128(2):178-184.
171. Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, et al. (2023) Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance. Hemasphere 7(6): e900.
172. Girolami A, Scandellari R, Zanon E, Sartori R, Girolami B (2006) Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases. J Thromb Thrombolysis 21(3):279-284.
173. Galipeau J, Sensebe L (2018) Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell 22(6): 824-833.
174. Liu WZ, Ma ZJ, Li JR, Kang XW (2021) Mesenchymal stem cell-derived exosomes: therapeutic opportunities and challenges for spinal cord injury. Stem Cell Res Ther 12(1): 102.
175. Brown C, McKee C, Bakshi S, Walker K, Hakman E, et al. (2019) Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med 13(9): 1738-1755.
176. Wang S, Lei B, Zhang E, Gong P, Gu J, et al. (2022) Targeted Therapy for Inflammatory Diseases with Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics. Int J Nanomedicine 17: 1757-1781.
177. Pathan M, Fonseka P, Chitti SV, Kang T, Sanwlani R, et al. (2019) Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res 47(D1): D516-D519.
178. Han Z, Chen H, Guo Z, Shen J, Luo W, et al. (2022) Circular RNAs and Their Role in Exosomes. Front Oncol 12: 848341.
179. Zhang J, Li S, Li L, Li M, Guo C, et al. (2015) Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics 13(1):17-24.
180. Qu Q, Wang L, Bing W, Bi Y, Zhang C, et al. (2020) miRNA-126-3p carried by human umbilical cord mesenchymal stem cell enhances endothelial function through exosome-mediated mechanisms in vitro and attenuates vein graft neointimal formation in vivo. Stem Cell Res Ther 11(1): 464.
181. Liu Y, Chen J, Liang H, Cai Y, Li X, et al. (2022) Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling. Stem Cell Res Ther 13(1): 258.
182. Liang Y, Duan L, Lu J, Xia J (2021) Engineering exosomes for targeted drug delivery. Theranostics 11(7): 3183-3195.
183. Guo L, Huang Z, Huang L, Liang J, Wang P, et al. (2021) Surface-modified engineered exosomes attenuated cerebral ischemia/reperfusion injury by targeting the delivery of quercetin towards impaired neurons. J Nanobiotechnology 19(1): 141.
184. Cheng HP, Siu LK, Chang FY (2003) Extended-spectrum cephalosporin compared to cefazolin for treatment of Klebsiella pneumoniae-caused liver abscess. Antimicrob Agents Chemother 47(7): 2088-2092.
185. IMbrave150 (2021) Exploratory Efficacy and Safety Results in Patients With Hepatocellular Carcinoma Without Macrovascular Invasion or Extrahepatic Spread Treated With Atezolizumab + Bevacizumab or Sorafenib. Gastroenterol Hepatol (N Y) 17(11 Suppl 6): 14-15.
186. Huang C, Zhu XD, Shen YH, Wu D, Ji Y, et al. (2021) Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res 9(1): 19.
187. Liu Q, Zhang Y, Zhang J, Chen L, Yang Y, et al. (2024) Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk. Front Oncol 14: 1374149.
188. Abouchaleh N, Gabr A, Ali R, Al Asadi A, Mora RA, et al. (2018) (90)Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. J Nucl Med 59(7): 1042-1048.
189. Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, et al. (2021) Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 27(12): 1758-1766.
190. Wu FX, Lu HR, Zhu SL, Li ZH, Zou L, et al. (2016) Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Onco Targets Ther 9: 7141-7147.
191. Marra P, Franchi-Abella S, Hernandez JA, Ronot M, Muglia R, D'Antiga L, et al. (2025) Percutaneous recanalization of non-cirrhotic extrahepatic portal vein obstruction in children: technical considerations in a preliminary cohort. Eur Radiol 35(6): 3262-3269.
192. Bernier MO, Hubert DLP, Michel C (2024) Risks of radiodiagnostic examinations in children. Rev Prat 74(1):69-73.
193. Giri S, Singh A, Kolhe K, Kale A, Shukla A (2023) Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis. J Gastroenterol Hepatol 38(10):1710-1717.
194. Garcia-Pagan JC, Hernandez-Guerra M, Bosch J (2008) Extrahepatic portal vein thrombosis. Semin Liver Dis 28(3): 282-292.
195. Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, et al. (2017) Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome. BMC Gastroenterol 17(1): 112.
196. Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H (2007) Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol 7: 34.
197. Kumar S, Sarr MG, Kamath PS (2001) Mesenteric venous thrombosis. N Engl J Med 345(23): 1683-1688.
198. Ogren M, Bergqvist D, Bjorck M, Acosta S, Sternby NH (2007) High incidence of concomitant venous thromboembolism in patients with portal vein thrombosis: a population study based on 23 796 consecutive autopsies. J Thromb Haemost 5(1): 198-200.
199. Koroneos A, Koutsoukou A, Zervakis D, Politis P, Sourlas S, et al. (2007) Successful resuscitation with thrombolysis of a patient suffering fulminant pulmonary embolism after recent intracerebral haemorrhage. Resuscitation 72(1): 154-157.
200. Kucher N, Rossi E, De Rosa M, Goldhaber SZ (2006) Massive pulmonary embolism. Circulation 113(4): 577-582.
201. Villa E, Camma C, Marietta M, Luongo M, Critelli R, et al. (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143(5): 1253-1260 e1254.
202. Wang L, Guo X, Xu X, Philips CA, Primignani M, et al. (2021) Association of portal venous system thrombosis with endoscopic variceal treatment: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 32(2): 125-131.
203. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D (2000) Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 32(3): 466-470.
204. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, et al. (2016) Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 65(5): 938-943.
205. Kupietzky A, Lehmann H, Hiller N, Ariche A (2021) Collateral damage: a case of pylephlebitis in the COVID-19 era. Hepatobiliary Surg Nutr 10(3): 418-420.
206. Ishikawa T, Sato R, Jimbo R, Kobayashi Y, Sato T, et al. (2024) Determinants of Survival of Ablation Treatment for Portal Vein Tumor Thrombus in Patients With Hepatocellular Carcinoma. In Vivo 38(5): 2501-2505.
207. Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, et al. (2019) Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol 4(9): 721-730.
208. Li X, Ye Z, Lin S, Pang H (2021) Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer 21(1): 701.
209. Zhang S, Zhong X, Zhong H, Zhong L, Li J, et al. (2023) Predicting the risk of variceal rehemorrhage in cirrhotic patients with portal vein thrombosis: A two-center retrospective study. J Dig Dis 24(11): 619-629.
210. Attanasi ML, Bou Daher H, Rockey DC (2023) Natural History and Outcomes of Cavernous Transformation of the Portal Vein in Cirrhosis. Dig Dis Sci 68(8): 3458-3466.
211. Mukund A, Marri UK, Jindal A, Choudhury A, Patidar Y, et al. (2023) Safety and Efficacy of Transjugular Intrahepatic Portosystemic Shunt for Non-tumoral Cirrhotic Portal Vein Thrombosis Not Responding to Anticoagulation Therapy. Dig Dis Sci 68(7): 3174-3184.
212. Subbaiah M, Kumar S, Roy KK, Sharma JB, Singh N (2015) Extrahepatic portal-vein obstruction in pregnancy. Taiwan J Obstet Gynecol 54(4): 394-397.
213. Rhee RY, Gloviczki P, Mendonca CT, Petterson TM, Serry RD, et al. (1994) Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg 20(5): 688-697.
214. Sharma B, Raina S, Sharma R (2014) Bleeding ectopic varices as the first manifestation of portal hypertension. Case Reports Hepatol 2014: 140959.
215. Sarin SK, Kumar CKN (2012) Ectopic varices. Clin Liver Dis (Hoboken) 1(5): 167-172.
216. Brook I, Gluck RS (1980) Clostridium paraputrificum sepsis in sickle cell anemia. South Med J 73(12): 1644-1645.
217. Mirza NN, McCloud JM, Cheetham MJ (2009) Clostridium septicum sepsis and colorectal cancer - a reminder. World J Surg Oncol 7: 73.
218. Tranah TH, Nayagam JS, Gregory S, Hughes S, Patch D, et al. (2023) Diagnosis and management of ectopic varices in portal hypertension. Lancet Gastroenterol Hepatol 8(11): 1046-1056.
219. Alcala L, Marin M, Ruiz A, Quiroga L, Zamora-Cintas M, et al. (2021) Identifying Anaerobic Bacteria Using MALDI-TOF Mass Spectrometry: A Four-Year Experience. Front Cell Infect Microbiol 11: 521014.
220. Rodriguez-Sanchez B, Alcala L, Marin M, Ruiz A, Alonso E, et al. (2016) Evaluation of MALDI-TOF MS (Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry) for routine identification of anaerobic bacteria. Anaerobe 42: 101-107.
221. Lisman T, Caldwell SH, Intagliata NM (2022) Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol 76(6):1291-1305.
222. Driever EG, Magaz M, Adelmeijer J, Turon F, Baiges A, et al. (2022) The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study. J Thromb Haemost 20(9): 2075-2082.
223. Baiges A, Procopet B, Silva-Junior G, Llop E, Tellez L, et al. (2023) Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis. J Hepatol 78(1): 114-122.
224. Ageno W, Beyer Westendorf J, Contino L, Bucherini E, Sartori MT, et al. (2022) Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Adv 6(12): 3569-3578.